Why use it

BMI alone is an inadequate predictor of obesity-related risk. Two individuals with identical BMIs may have vastly different metabolic and clinical risk profiles (the "obesity paradox"). EOSS stratifies patients by actual disease burden, enabling treatment prioritization: low-stage patients may require lifestyle intervention only, while high-stage patients require intensive medical therapy or bariatric surgery. EOSS also incorporates psychological health, recognizing depression and eating disorders as drivers of poor outcomes.

About

The Edmonton Obesity Staging System (EOSS) is a clinical staging system developed by Sharma and Kushner to classify obesity not by body mass index alone, but by the presence and severity of obesity-related comorbidities, functional limitations, and psychological burden. It assigns a stage from 0 to 4 based on the most severe comorbidity present across metabolic, mechanical, and mental health domains. EOSS provides a clinically meaningful framework that predicts all-cause mortality independently of BMI: patients with Class III obesity (BMI ≥40) at EOSS Stage 0–1 have better survival than normal-weight individuals at EOSS Stage 3–4. This challenges the sole reliance on BMI for risk stratification and treatment prioritization in obesity management. EOSS is endorsed by Obesity Canada and is incorporated into Canadian clinical practice guidelines for obesity management.

When to use

Initial obesity assessment in any patient with BMI ≥30 (or ≥27 with comorbidities)
Determining the appropriate intensity of weight management intervention
Evaluating candidacy for bariatric surgery or pharmacotherapy
Risk stratification in patients where BMI does not reflect clinical severity
Follow-up monitoring of treatment response in obesity management programs
Multidisciplinary weight management team case review and treatment planning

Formula

EOSS Stage is assigned based on the MOST SEVERE finding across all domains: Stage 0: No obesity-related risk factors, no physical symptoms, no psychological impairment Stage 1: Subclinical risk factors (pre-diabetes, elevated BP without threshold, dyslipidemia), mild physical symptoms, mild psychological distress Stage 2: Established obesity-related chronic diseases (T2DM, hypertension, sleep apnea, GERD, osteoarthritis), moderate limitations in daily activities, moderate psychological impairment Stage 3: Established end-organ damage (MI, stroke, HF, advanced DM complications, significant musculoskeletal disease), significant functional impairment, severe psychological impairment Stage 4: Potentially end-stage disability from obesity-related chronic disease, severe functional limitations, severe disabling psychopathology

Pearls & pitfalls

EOSS stage is determined by the MOST SEVERE domain finding — a patient with mild metabolic disease (Stage 1) but severe depression (Stage 3) is assigned Stage 3.
Large prospective studies (Padwal et al. NHANES 2009) showed EOSS predicts mortality independently of BMI — EOSS outperforms BMI for risk stratification.
A patient with morbid obesity (BMI 50) but EOSS Stage 0–1 has a better prognosis than a normal-weight individual with EOSS Stage 3.
Psychological comorbidity (depression, anxiety, binge eating disorder, eating disorder NOS) is often underweighted in obesity assessment — EOSS explicitly includes it.
EOSS Stage 2 corresponds roughly to the threshold where pharmacotherapy becomes appropriate (GLP-1 agonists, naltrexone/bupropion, orlistat).
Bariatric surgery is generally recommended from Stage 2 (BMI ≥35) and should be urgently discussed from Stage 3 regardless of BMI class.
EOSS does NOT replace BMI — it is used in addition to BMI to provide a complete clinical picture.
Re-staging after treatment intervention tracks treatment response and guides escalation or de-escalation of therapy.

Next steps

Stage 0: Lifestyle modification (diet, exercise, behavioral). No pharmacotherapy or surgery indicated. Stage 1: Intensive lifestyle intervention. Address risk factors before they become established comorbidities. Stage 2: Medical treatment of obesity and comorbidities; pharmacotherapy considered; bariatric surgery assessment if BMI ≥35. Stage 3: Aggressive management of comorbidities; bariatric surgery strongly considered (BMI ≥35 or ≥30 with severe comorbidities). Stage 4: Intensive treatment of end-stage comorbidities; bariatric surgery may be high-risk but still considered in select patients; palliative and supportive care may be appropriate.

Evidence

Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes. 2009;33(3):289-295. PMID:19188927. Validated in NHANES cohort (Padwal RS et al. CMAJ. 2011;183(14):E1059-E1066; n=8143): EOSS independently predicted mortality (HR 1.5 per stage increase, p<0.001) after adjusting for BMI, waist circumference, and metabolic syndrome. High-stage individuals at all BMI levels had higher mortality than lower-stage individuals.

References

Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes. 2009;33(3):289-295. — link
Padwal RS et al. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183(14):E1059-E1066. — link
Kuk JL et al. Edmonton obesity staging system: association with weight history and mortality risk. Appl Physiol Nutr Metab. 2011;36(4):570-576. — link

Edmonton Obesity Staging System (EOSS)

Calculator